Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Comments
Loading...
Rocket Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:RCKT | Benzinga
Rocket Pharmaceuticals Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for Rocket Pharmaceuticals Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Scotiabank
Canaccord Genuity
Chardan Capital
JP Morgan
Goldman Sachs
1calculated from analyst ratings
Analyst Ratings for Rocket Pharmaceuticals
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/12/2025 | Buy Now | — | Scotiabank | Greg Harrison11% | $52 → $51 | Maintains | Sector Outperform | Get Alert |
| 05/12/2025 | Buy Now | — | Canaccord Genuity | Whitney Ijem51% | $36 → $34 | Maintains | Buy | Get Alert |
| 05/09/2025 | Buy Now | — | Chardan Capital | Geulah Livshits54% | $54 → $45 | Maintains | Buy | Get Alert |
| 05/09/2025 | Buy Now | — | JP Morgan | Eric Joseph22% | $45 → $44 | Maintains | Overweight | Get Alert |
| 05/09/2025 | Buy Now | — | Goldman Sachs | Richard Law62% | $15 → $13 | Maintains | Neutral | Get Alert |
| 04/09/2025 | Buy Now | — | Needham | Gil Blum54% | $42 → $42 | Reiterates | Buy → Buy | Get Alert |
| 03/12/2025 | Buy Now | — | BMO Capital | Kostas Biliouris32% | → $50 | Initiates | → Outperform | Get Alert |
| 03/03/2025 | Buy Now | — | Scotiabank | Greg Harrison11% | $51 → $52 | Maintains | Sector Outperform | Get Alert |
| 03/03/2025 | Buy Now | — | Goldman Sachs | Richard Law62% | $29 → $15 | Maintains | Neutral | Get Alert |
| 03/03/2025 | Buy Now | — | Canaccord Genuity | Whitney Ijem51% | $39 → $36 | Maintains | Buy | Get Alert |
| 02/28/2025 | Buy Now | — | Chardan Capital | Geulah Livshits54% | $62 → $54 | Maintains | Buy | Get Alert |
| 02/28/2025 | Buy Now | — | Needham | Gil Blum54% | $52 → $42 | Maintains | Buy | Get Alert |
| 12/18/2024 | Buy Now | — | Jefferies | Andrew Tsai27% | → $29 | Initiates | → Buy | Get Alert |
| 11/19/2024 | Buy Now | — | Canaccord Genuity | Whitney Ijem51% | $39 → $39 | Maintains | Buy | Get Alert |
| 11/19/2024 | Buy Now | — | Leerink Partners | Mani Foroohar49% | $46 → $44 | Maintains | Outperform | Get Alert |
| 11/19/2024 | Buy Now | — | Cantor Fitzgerald | Josh Schimmer60% | $65 → $65 | Reiterates | Overweight → Overweight | Get Alert |
| 11/19/2024 | Buy Now | — | Needham | Gil Blum54% | $52 → $52 | Reiterates | Buy → Buy | Get Alert |
| 11/18/2024 | Buy Now | — | Chardan Capital | Geulah Livshits54% | $62 → $62 | Maintains | Buy | Get Alert |
| 11/11/2024 | Buy Now | — | Chardan Capital | Geulah Livshits54% | $62 → $62 | Maintains | Buy | Get Alert |
| 11/08/2024 | Buy Now | — | Needham | Gil Blum54% | $52 → $52 | Reiterates | Buy → Buy | Get Alert |
| 10/16/2024 | Buy Now | — | Scotiabank | Greg Harrison11% | → $50 | Initiates | → Sector Outperform | Get Alert |
| 09/30/2024 | Buy Now | — | Canaccord Genuity | Whitney Ijem51% | $38 → $38 | Maintains | Buy | Get Alert |
| 09/17/2024 | Buy Now | — | Needham | Gil Blum54% | $52 → $52 | Reiterates | Buy → Buy | Get Alert |
| 08/06/2024 | Buy Now | — | JP Morgan | Eric Joseph22% | $50 → $54 | Maintains | Overweight | Get Alert |
| 08/06/2024 | Buy Now | — | Cantor Fitzgerald | Josh Schimmer60% | $65 → $65 | Reiterates | Overweight → Overweight | Get Alert |
| 08/06/2024 | Buy Now | — | Chardan Capital | Geulah Livshits54% | $62 → $62 | Maintains | Buy | Get Alert |
| 08/06/2024 | Buy Now | — | Needham | Gil Blum54% | $52 → $52 | Reiterates | Buy → Buy | Get Alert |
| 07/03/2024 | Buy Now | — | Canaccord Genuity | Whitney Ijem51% | $49 → $40 | Maintains | Buy | Get Alert |
| 06/28/2024 | Buy Now | — | Chardan Capital | Geulah Livshits54% | $62 → $62 | Maintains | Buy | Get Alert |
| 06/28/2024 | Buy Now | — | Needham | Gil Blum54% | $53 → $52 | Maintains | Buy | Get Alert |
| 05/07/2024 | Buy Now | — | Needham | Gil Blum54% | $53 → $53 | Reiterates | Buy → Buy | Get Alert |
| 04/10/2024 | Buy Now | — | Needham | Gil Blum54% | $53 → $53 | Reiterates | Buy → Buy | Get Alert |
| 04/02/2024 | Buy Now | — | Goldman Sachs | Richard Law62% | → $39 | Initiates | → Neutral | Get Alert |
| 03/01/2024 | Buy Now | — | UBS | Colin Bristow41% | $56 → $54 | Maintains | Buy | Get Alert |
| 02/27/2024 | Buy Now | — | JP Morgan | Eric Joseph22% | $55 → $50 | Maintains | Overweight | Get Alert |
| 02/27/2024 | Buy Now | — | Cantor Fitzgerald | Josh Schimmer60% | $65 → $65 | Maintains | Overweight | Get Alert |
| 02/13/2024 | Buy Now | — | Needham | Gil Blum54% | $53 → $53 | Reiterates | Buy → Buy | Get Alert |
| 01/31/2024 | Buy Now | — | Cantor Fitzgerald | Louise Chen42% | $65 → $65 | Reiterates | Overweight → Overweight | Get Alert |
| 11/07/2023 | Buy Now | — | Needham | Gil Blum54% | → $53 | Reiterates | Buy → Buy | Get Alert |
| 10/24/2023 | Buy Now | — | Cantor Fitzgerald | Josh Schimmer60% | → $65 | Initiates | → Overweight | Get Alert |
| 09/13/2023 | Buy Now | — | Stifel | Dae Gon Ha41% | → $48 | Reiterates | Buy → Buy | Get Alert |
| 09/13/2023 | Buy Now | — | Needham | Gil Blum54% | $60 → $53 | Maintains | Buy | Get Alert |
| 08/11/2023 | Buy Now | — | Canaccord Genuity | Whitney Ijem51% | $49 → $47 | Maintains | Buy | Get Alert |
| 08/11/2023 | Buy Now | — | Chardan Capital | Geulah Livshits54% | → $61 | Reiterates | Buy → Buy | Get Alert |
| 08/10/2023 | Buy Now | — | Needham | Gil Blum54% | → $60 | Reiterates | Buy → Buy | Get Alert |
| 08/10/2023 | Buy Now | — | Stifel | Dae Gon Ha41% | $53 → $48 | Maintains | Buy | Get Alert |
| 05/23/2023 | Buy Now | — | Needham | Gil Blum54% | → $60 | Reiterates | Buy → Buy | Get Alert |
| 05/08/2023 | Buy Now | — | Chardan Capital | Geulah Livshits54% | $63 → $61 | Maintains | Buy | Get Alert |
| 05/05/2023 | Buy Now | — | Raymond James | Steven Seedhouse63% | $33 → $35 | Maintains | Outperform | Get Alert |
| 05/05/2023 | Buy Now | — | Needham | Gil Blum54% | → $60 | Reiterates | → Buy | Get Alert |
| 04/19/2023 | Buy Now | — | Needham | Gil Blum54% | → $60 | Reiterates | → Buy | Get Alert |
| 03/01/2023 | Buy Now | — | Chardan Capital | Geulah Livshits54% | $65 → $63 | Reiterates | → Buy | Get Alert |
| 02/28/2023 | Buy Now | — | Needham | Gil Blum54% | → $60 | Reiterates | → Buy | Get Alert |
| 02/01/2023 | Buy Now | — | Morgan Stanley | Michael Ulz69% | → $45 | Initiates | → Overweight | Get Alert |
| 01/23/2023 | Buy Now | — | SVB Leerink | Mani Foroohar49% | $50 → $49 | Maintains | Outperform | Get Alert |
| 12/23/2022 | Buy Now | — | B of A Securities | Greg Harrison11% | $38 → $35 | Maintains | Buy | Get Alert |
| 12/22/2022 | Buy Now | — | SVB Leerink | Mani Foroohar49% | $54 → $50 | Maintains | Outperform | Get Alert |
| 12/06/2022 | Buy Now | — | SVB Leerink | Mani Foroohar49% | $56 → $54 | Maintains | Outperform | Get Alert |
| 11/08/2022 | Buy Now | — | Canaccord Genuity | Whitney Ijem51% | → $53 | Initiates | → Buy | Get Alert |
| 11/07/2022 | Buy Now | — | Raymond James | Steven Seedhouse63% | $34 → $33 | Maintains | Outperform | Get Alert |
| 11/04/2022 | Buy Now | — | Needham | Gil Blum54% | $62 → $60 | Maintains | Buy | Get Alert |
| 11/01/2022 | Buy Now | — | BTIG | Yun Zhong34% | → $35 | Initiates | → Buy | Get Alert |
| 10/03/2022 | Buy Now | — | Chardan Capital | Geulah Livshits54% | $62 → $65 | Maintains | Buy | Get Alert |
| 10/03/2022 | Buy Now | — | Raymond James | Steven Seedhouse63% | $24 → $34 | Maintains | Outperform | Get Alert |
| 09/30/2022 | Buy Now | — | SVB Leerink | Mani Foroohar49% | $65 → $60 | Maintains | Outperform | Get Alert |
| 09/30/2022 | Buy Now | — | Evercore ISI Group | Joshua Schimmer43% | $65 → $75 | Maintains | Outperform | Get Alert |
| 09/27/2022 | Buy Now | — | UBS | Colin Bristow41% | $68 → $62 | Maintains | Buy | Get Alert |
| 08/09/2022 | Buy Now | — | Raymond James | Steven Seedhouse63% | $22 → $24 | Maintains | Outperform | Get Alert |
| 07/26/2022 | Buy Now | — | Stifel | Dae Gon Ha41% | $67 → $56 | Maintains | Buy | Get Alert |
| 07/08/2022 | Buy Now | — | Raymond James | Timur Ivannikov31% | → $22 | Initiates | → Outperform | Get Alert |
| 07/06/2022 | Buy Now | — | SVB Leerink | Mani Foroohar49% | $66 → $64 | Maintains | Outperform | Get Alert |
| 05/20/2022 | Buy Now | — | Chardan Capital | Geulah Livshits54% | $60 → $62 | Maintains | Buy | Get Alert |
| 05/20/2022 | Buy Now | — | SVB Leerink | Mani Foroohar49% | $64 → $66 | Maintains | Outperform | Get Alert |
| 05/17/2022 | Buy Now | — | Needham | Gil Blum54% | $75 → $62 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Rocket Pharmaceuticals (RCKT) stock?
The latest price target for Rocket Pharmaceuticals (NASDAQ:RCKT) was reported by Scotiabank on May 12, 2025. The analyst firm set a price target for $51.00 expecting RCKT to rise to within 12 months (a possible 727.25% upside). 30 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Rocket Pharmaceuticals (RCKT)?
The latest analyst rating for Rocket Pharmaceuticals (NASDAQ:RCKT) was provided by Scotiabank, and Rocket Pharmaceuticals maintained their sector outperform rating.
When was the last upgrade for Rocket Pharmaceuticals (RCKT)?
There is no last upgrade for Rocket Pharmaceuticals
When was the last downgrade for Rocket Pharmaceuticals (RCKT)?
There is no last downgrade for Rocket Pharmaceuticals.
When is the next analyst rating going to be posted or updated for Rocket Pharmaceuticals (RCKT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Rocket Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Rocket Pharmaceuticals was filed on May 12, 2025 so you should expect the next rating to be made available sometime around May 12, 2026.
Is the Analyst Rating Rocket Pharmaceuticals (RCKT) correct?
While ratings are subjective and will change, the latest Rocket Pharmaceuticals (RCKT) rating was a maintained with a price target of $52.00 to $51.00. The current price Rocket Pharmaceuticals (RCKT) is trading at is $6.17, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
